Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Oncotelic Therapeutics Inc
OTLCOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies. The company is headquartered in Agoura Hills, California. Address: 29397 Agoura Road, Agoura Hills, CA, United States, 91301
Analytics
Precio Objetivo de WallStreet
4 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave OTLC
Análisis de dividendos OTLC
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout OTLC
Valoración de la acción OTLC
Finanzas OTLC
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |